VRCA
Verrica Pharmaceuticals Inc
NASDAQ: VRCA · HEALTHCARE · BIOTECHNOLOGY
$6.37
-3.19% today
Updated 2026-04-30
Market cap
$112.18M
P/E ratio
—
P/S ratio
3.15x
EPS (TTM)
$-1.68
Dividend yield
—
52W range
$3 – $10
Volume
0.1M
WallStSmart proprietary scores
31
out of 100
Grade: F
Strong Sell
Investment rating
8.0
Growth
A5.5
Quality
C+2.0
Profitability
F6.7
Valuation
B5/9
Piotroski F-Score
Moderate
-7.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$16.50
+159.03%
12-Month target
—
—
Intrinsic (DCF)
$28.00
Margin of safety
+80.14%
0 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 1,380.00% QoQ
+ 80.14% below intrinsic value
+ Debt/equity -2.10x — low leverage
Risks
- Altman Z -7.52 — distress zone
- Thin margins at -50.30%
- Negative free cash flow $-4.59M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $9.03M | $5.12M | $7.57M | $35.58M | $35.58M |
| Net income | $-24.49M | $-67.00M | $-76.58M | $-17.89M | $-8.07M |
| EPS | — | — | — | — | $-1.68 |
| Free cash flow | $-18.95M | $-38.94M | $-60.95M | $-17.63M | $-4.59M |
| Profit margin | -271.11% | -1,307.47% | -1,012.15% | -50.27% | -50.30% |
Peer comparison
Smart narrative
Verrica Pharmaceuticals Inc trades at $6.37. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -7.52, it sits in the distress. TTM revenue stands at $35.58M. with profit margins at -50.30%. Our DCF model estimates intrinsic value at $28.00.
Frequently asked questions
What is Verrica Pharmaceuticals Inc's stock price?
Verrica Pharmaceuticals Inc (VRCA) trades at $6.37.
Is Verrica Pharmaceuticals Inc overvalued?
Smart Value Score 31/100 (Grade F, Strong Sell). DCF value $28.00.
What is the price target of Verrica Pharmaceuticals Inc (VRCA)?
The analyst target price is $16.50, representing +159.0% upside from the current price of $6.37.
What is the intrinsic value of Verrica Pharmaceuticals Inc (VRCA)?
Based on our DCF model, intrinsic value is $28.00, a +80.1% margin of safety versus $6.37.
What is Verrica Pharmaceuticals Inc's revenue?
TTM revenue is $35.58M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
-7.52 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.15x
ROE-240.40%
Beta1.43
50D MA$5.71
200D MA$5.93
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—